{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:22:29Z","timestamp":1774606949733,"version":"3.50.1"},"reference-count":103,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014069","name":"Funda\u00e7\u00e3o Champalimaud","doi-asserted-by":"publisher","award":["168"],"award-info":[{"award-number":["168"]}],"id":[{"id":"10.13039\/501100014069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["FCT-PTDC\/MEC-ONC\/31627\/2017"],"award-info":[{"award-number":["FCT-PTDC\/MEC-ONC\/31627\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["Congento (LISBOA-01-0145-FEDER-022170"],"award-info":[{"award-number":["Congento (LISBOA-01-0145-FEDER-022170"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Poly (ADP-ribose) polymerase (PARP) inhibition in BRCA-mutated cells results in an incapacity to repair DNA damage, leading to cell death caused by synthetic lethality. Within the treatment options for advanced triple negative breast cancer, the PARP inhibitor olaparib is only given to patients with BRCA1\/2 mutations. However, these patients may show resistance to this drug and BRCA1\/2 wild-type tumors can show a striking sensitivity, making BRCA status a poor biomarker for treatment choice. Aiming to investigate if the zebrafish model can discriminate sensitivities to olaparib, we developed zebrafish xenografts with different BRCA status and measured tumor response to treatment, as well as its impact on angiogenesis and metastasis. When challenged with olaparib, xenografts revealed sensitivity phenotypes independent of BRCA. Moreover, its combination with ionizing radiation increased the cytotoxic effects, showing potential as a combinatorial regimen. In conclusion, we show that the zebrafish xenograft model may be used as a sensitivity profiling platform for olaparib in monotherapy or in combinatorial regimens. Hence, this model presents as a promising option for the future establishment of patient-derived xenografts for personalized medicine approaches beyond BRCA status.<\/jats:p>","DOI":"10.3390\/cancers12071769","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T09:49:11Z","timestamp":1594028951000},"page":"1769","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status"],"prefix":"10.3390","volume":"12","author":[{"given":"Ana Beatriz","family":"Varanda","sequence":"first","affiliation":[{"name":"Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal"}]},{"given":"Ana","family":"Martins-Logrado","sequence":"additional","affiliation":[{"name":"Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8363-7183","authenticated-orcid":false,"given":"Miguel","family":"Godinho Ferreira","sequence":"additional","affiliation":[{"name":"Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal"},{"name":"Institute for Research on Cancer and Aging of Nice (IRCAN), Universit\u00e9 C\u00f4te d\u2019Azur, U1081 UMR7284 UNS, 06107 Nice, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5550-2428","authenticated-orcid":false,"given":"Rita","family":"Fior","sequence":"additional","affiliation":[{"name":"Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","article-title":"Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer","volume":"2","author":"Chen","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","article-title":"Repair Pathway Choices and Consequences at the Double-Strand Break","volume":"26","author":"Ceccaldi","year":"2016","journal-title":"Trends Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA 2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"ref_6","unstructured":"Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., Andr\u00e9, F., Harbeck, N., Lopez, B.A., Barrios, C.H., and Bergh, J. (2018). ESMO Clinical Practice Guidelines Slideset\u2014Advanced Breast Cancer. ESMO."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Min, A., and Im, S.A. (2020). PARP inhibitors as therapeutics: Beyond modulation of parylation. Cancers (Basel), 12.","DOI":"10.3390\/cancers12020394"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Keung, M.Y., Wu, Y., Badar, F., and Vadgama, J.V. (2020). Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040940"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_11","first-page":"2","article-title":"Clinical Strategies for PARP Inhibitors beyond Homologous Recombination Deficiency","volume":"1","author":"Helleday","year":"2018","journal-title":"J. Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-019-0285-2","article-title":"Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy","volume":"16","author":"Curtin","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/jco.2010.28.15_suppl.3002","article-title":"Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer","volume":"28","author":"Gelmon","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1470-2045(19)30780-6","article-title":"The tip of the iceberg: Predicting PARP inhibitor efficacy in prostate cancer","volume":"21","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41467-019-09232-8","article-title":"The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors","volume":"10","author":"Peng","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1158\/0008-5472.CAN-18-0633","article-title":"Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention","volume":"78","author":"Ali","year":"2018","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","article-title":"The BRCA1-\u039411q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI70196","article-title":"BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1","volume":"126","author":"Drost","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Chaudhuri","year":"2016","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ncb3626","article-title":"EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation","volume":"19","author":"Rondinelli","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nsmb.1831","article-title":"53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers","volume":"17","author":"Bouwman","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 counteracts DNA double-strand break resection and affects PARP inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e9172","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Cruz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"15","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102578","DOI":"10.1016\/j.ebiom.2019.11.039","article-title":"Developments in zebrafish avatars as radiotherapy sensitivity reporters\u2014Towards personalized medicine","volume":"51","author":"Costa","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E8234","DOI":"10.1073\/pnas.1618389114","article-title":"Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts","volume":"114","author":"Fior","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Costa, B., Estrada, M.F., Mendes, R.V., and Fior, R. (2020). Zebrafish Avatars towards Personalized Medicine\u2014A Comparative Review between Avatar Models. Cells, 9.","DOI":"10.3390\/cells9020293"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41568-020-0252-3","article-title":"Zebrafish patient avatars in cancer biology and precision cancer therapy","volume":"20","author":"Fazio","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mart\u00ed, J.M., Fern\u00e1ndez-Cort\u00e9s, M., Serrano-S\u00e1enz, S., Zamudio-Martinez, E., Delgado-Bellido, D., Garcia-Diaz, A., and Oliver, F.J. (2020). The multifactorial role of PARP-1 in tumor microenvironment. Cancers (Basel), 12.","DOI":"10.3390\/cancers12030739"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2013.00290","article-title":"Beyond DNA repair: Additional functions of PARP-1 in cancer","volume":"3","author":"Weaver","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/23723556.2019.1585170","article-title":"Beyond DNA repair: The novel immunological potential of PARP inhibitors","volume":"6","author":"Chabanon","year":"2019","journal-title":"Mol. Cell. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrc3891","article-title":"Therapeutic opportunities within the DNA damage response","volume":"15","author":"Pearl","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/mutage\/geg032","article-title":"Brca2 (XRCC11) deficiency results in enhanced mutagenesis","volume":"18","author":"Wiegant","year":"2003","journal-title":"Mutagenesis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","article-title":"Ki-67: More than a proliferation marker","volume":"127","author":"Sun","year":"2018","journal-title":"Chromosoma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1006\/gyno.2002.6646","article-title":"Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer","volume":"85","author":"Levine","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"van der Groep, P., van Diest, P.J., Smolders, Y.H.C.M., Ausems, M.G.E.M., van der Luijt, R.B., Menko, F.H., Bart, J., de Vries, E.G.E., and van der Wall, E. (2013). HIF-1\u03b1 Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056055"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Saponaro, C., Malfettone, A., Ranieri, G., Danza, K., Simone, G., Paradiso, A., and Mangia, A. (2013). VEGF, HIF-1\u03b1 Expression and MVD as an Angiogenic Network in Familial Breast Cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053070"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/dbio.2002.0711","article-title":"In vivo imaging of embryonic vascular development using transgenic zebrafish","volume":"248","author":"Lawson","year":"2002","journal-title":"Dev. Biol."},{"key":"ref_46","first-page":"1586","article-title":"Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions","volume":"24","author":"Basourakos","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1541-7786.MCR-11-0477","article-title":"Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts","volume":"10","author":"Kedar","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4161\/cc.24034","article-title":"Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer","volume":"12","author":"Michels","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/cam4.1318","article-title":"PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation","volume":"7","author":"Mao","year":"2018","journal-title":"Cancer Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijrobp.2013.02.015","article-title":"In vitro and in vivo enhancement of chemoradiation using the oral parp inhibitor ABT-888 in colorectal cancer cells","volume":"86","author":"Shelton","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s10637-011-9770-x","article-title":"MK-4827, a PARP-1\/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation","volume":"30","author":"Wang","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1158\/1535-7163.MCT-11-0278","article-title":"Inhibition of poly (ADP-ribose) polymerase-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft","volume":"10","author":"Senra","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_54","unstructured":"European Medicines Agency (2020, May 03). Lynparza: EPAR\u2014Product Information. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza#product-information-section."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/44188","article-title":"14-3-3\u03c3 is required to prevent mitotic catastrophe after DNA damage","volume":"401","author":"Chan","year":"1999","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrm2651","article-title":"The emerging role of nuclear architecture in DNA repair and genome maintenance","volume":"10","author":"Misteli","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0968-4328(99)00083-9","article-title":"Radiation response of cell organelles","volume":"31","author":"Somosy","year":"2000","journal-title":"Micron"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1021\/acs.bioconjchem.0c00119","article-title":"Imaging Cell Death: Focus on Early Evaluation of Tumor Response to Therapy","volume":"31","author":"Zhang","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","article-title":"Drug-Induced death signaling strategy rapidly predicts cancer response to chemotherapy","volume":"160","author":"Montero","year":"2015","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1021\/jacs.0c01622","article-title":"Platinum-triggered Bond-cleavage of Pentynoyl amide and N-propargyl handles for Drug-Activation","volume":"142","author":"Oliveira","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u201cBRCAness\u201d in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bcp.2019.03.028","article-title":"Mitotic functions of poly(ADP-ribose) polymerases","volume":"167","author":"Slade","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15981","article-title":"Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells","volume":"8","author":"Schoonen","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"103931","DOI":"10.18632\/oncotarget.21879","article-title":"PARP inhibition causes premature loss of cohesion in cancer cells","volume":"8","author":"Kukolj","year":"2017","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lafontaine, J., Boisvert, J.S., Glory, A., Coulombe, S., and Wong, P. (2020). Synergy between non-thermal plasma with radiation therapy and olaparib in a panel of breast cancer cell lines. Cancers (Basel), 12.","DOI":"10.3390\/cancers12020348"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1158\/0008-5472.CAN-05-3050","article-title":"Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis","volume":"66","author":"Villuendas","year":"2006","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/onc.2013.9","article-title":"Interaction between PARP-1 and HIF-2 in the hypoxic response","volume":"33","author":"Siles","year":"2014","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jvs.2016.03.407","article-title":"Poly-ADP-ribose polymerase inhibition enhances ischemic and diabetic wound healing by promoting angiogenesis","volume":"65","author":"Zhou","year":"2017","journal-title":"J. Vasc. Surg."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2397","article-title":"Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response","volume":"8","author":"Dewhirst","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1126\/science.1060191","article-title":"Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice","volume":"293","author":"Paris","year":"2001","journal-title":"Science (80-)"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2045-824X-5-19","article-title":"The effects of radiation on angiogenesis","volume":"5","author":"Grabham","year":"2013","journal-title":"Vasc. Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ni1007","article-title":"Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants","volume":"4","author":"Traver","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Schacke, M., Kumar, J., Colwell, N., Hermanson, K., Folle, G.A., Nechaev, S., Dhasarathy, A., and Lafon-Hughes, L. (2019). PARP-1\/2 inhibitor olaparib prevents or partially reverts EMT induced by TGF-\u03b2 in NMuMG cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030518"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/carcin\/bgu183","article-title":"PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis","volume":"35","author":"Pu","year":"2014","journal-title":"Carcinogenesis"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s10020-018-0015-8","article-title":"Effects of radiation on the metastatic process","volume":"24","author":"Sundahl","year":"2018","journal-title":"Mol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"BSR20192226","DOI":"10.1042\/BSR20192226","article-title":"Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: A meta-analysis of nine randomized controlled trials","volume":"40","author":"Shao","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1530\/ERC-16-0116","article-title":"Evaluation of the methods to identify patients who may benefit from PARP inhibitor use","volume":"23","author":"Lim","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1541-7786.MCR-16-0108","article-title":"Olaparib, monotherapy or with ionizing radiation, exacerbates DNA damage in normal tissues: Insights from a new p21 reporter mouse","volume":"14","author":"McMahon","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ygyno.2018.07.002","article-title":"Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas","volume":"150","author":"Bi","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ijrobp.2016.01.035","article-title":"Hypoxia potentiates the radiation-sensitizing effect of olaparib in human non-small cell lung cancer xenografts by contextual synthetic lethality","volume":"95","author":"Jiang","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Lohse, I., Kumareswaran, R., Cao, P., Pitcher, B., Gallinger, S., Bristow, R.G., and Hedley, D.W. (2016). Effects of combined treatment with ionizing radiation and the PARP inhibitor olaparib in BRCA mutant and wild type patient-derived pancreatic cancer xenografts. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167272"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1073\/pnas.1500223112","article-title":"Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer","volume":"112","author":"Henneman","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/1940-6207.CAPR-14-0047","article-title":"The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice","volume":"7","author":"To","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Cornet, C., Dyballa, S., Terriente, J., and Di Giacomo, V. (2020). ZeOncoTest: Refining and automating the zebrafish xenograft model for drug discovery in cancer. Pharmaceuticals, 13.","DOI":"10.3390\/ph13010001"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Xiao, J., Glasgow, E., and Agarwal, S. (2020). Zebrafish Xenografts for Drug Discovery and Personalized Medicine. Trends Cancer.","DOI":"10.1016\/j.trecan.2020.03.012"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/d41573-019-00165-x","article-title":"Zebrafish earn their drug discovery stripes","volume":"18","author":"Cully","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Yan, C., Brunson, D.C., Tang, Q., Haber, D.A., Rawls, J.F., and Langenau, D.M. (2019). Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell, 1\u201312.","DOI":"10.1158\/1538-7445.CAMODELS2020-PR12"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1700082","DOI":"10.1002\/bies.201700082","article-title":"PTEN in the maintenance of genome integrity: From DNA replication to chromosome segregation","volume":"39","author":"Hou","year":"2017","journal-title":"BioEssays"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Martin","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1038\/srep10129","article-title":"Single cell resolution in vivo imaging of DNA damage following PARP inhibition","volume":"5","author":"Yang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"87044","DOI":"10.18632\/oncotarget.19667","article-title":"Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib","volume":"8","author":"Osoegawa","year":"2017","journal-title":"Oncotarget"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/0008-5472.CAN-18-2077","article-title":"Radiosensitivity is an acquired vulnerability of PARPI-resistant BRCA1-deficient tumors","volume":"79","author":"Barazas","year":"2019","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"De Haan, R., Van Werkhoven, E., Van Den Heuvel, M.M., Peulen, H.M.U., Sonke, G.S., Elkhuizen, P., Van Den Brekel, M.W.M., Tesselaar, M.E.T., Vens, C., and Schellens, J.H.M. (2019). Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6121-3"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/1535-7163.MCT-19-0520","article-title":"PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation","volume":"18","author":"Michmerhuizen","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_100","first-page":"12","article-title":"PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status","volume":"8","author":"Fulton","year":"2018","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5413-y","article-title":"Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol","volume":"19","author":"Lesueur","year":"2019","journal-title":"BMC Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fphar.2020.00170","article-title":"Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy","volume":"11","author":"Jannetti","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.stem.2007.11.002","article-title":"Transparent Adult Zebrafish as a Tool for In Vivo Transplantation Analysis","volume":"2","author":"White","year":"2008","journal-title":"Cell Stem Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1769\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:46:34Z","timestamp":1760175994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":103,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["cancers12071769"],"URL":"https:\/\/doi.org\/10.3390\/cancers12071769","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}